RAF265
RAF265 (CHIR-265) is a potent dual inhibitor targeting Raf kinases (C-Raf, B-Raf, B-Raf V600E) and VEGFR2, with IC50 values in the low nanomolar range. This compound has been investigated in Phase 2 clinical studies for oncology research, supporting its use in both in vitro biochemical assays and in vivo models of cancer and angiogenesis.
Product Specifications
CAS Number
927880-90-8
Product Name Alternative
Raf, Raf kinases, RAF 265, RAF265, RAF-265, VEGFR, VEGFR2, Vascular endothelial growth factor receptor, Inhibitor, inhibit, CHIR 265, CHIR265, CHIR-265, Autophagy, Apoptosis, B-Raf
Field of Research
Cardiovascular Research, Cell Biology, Signal Transduction
Purity
99.18% (May vary between batches)
Solubility
Ethanol:10.4 mg/mL (20.06 mM) ; DMSO:51.8 mg/mL (99.92 mM)
Smiles
Cn1c (Nc2ccc (cc2) C (F) (F) F) nc2cc (Oc3ccnc (c3) -c3ncc ([nH]3) C (F) (F) F) ccc12
Molecular Formula
C24H16F6N6O
Molecular Weight
518.41
Storage Conditions
-20°C
Notes
For research use only.
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
A1327-02G1-PE 100 µL
Albumin, Human Serum (HSA, ALB, Analbuminemia, DKFZp779N1935, Dysalbuminemic Hyperthyroxinemia, Growth Inhibiting Protein 20, Hyperthyroxinemia Dysalbuminemic, PRO0883, PRO0903, PRO1341, PRO2044, PRO2619) (PE) discontinued
Sign In for Pricing
View Details 
